104
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Pharmacophore mapping and in silico screening to identify new potent leads for A2A adenosine receptor as antagonists

, , &
Pages 102-113 | Received 07 Oct 2011, Accepted 13 Dec 2011, Published online: 02 Mar 2012
 

Abstract

A2A adenosine receptor (AR) antagonists play an important role in neurodegenerative diseases like Parkinson’s disease. A 3D-QSAR study of A2A AR antagonists, was taken up to design best pharmacophore model. The pharmacophoric features (ADHRR) containing a hydrogen bond acceptor (A), a hydrogen bond donor (D), a hydrophobic group (H) and two aromatic rings (R), is projected as the best predictive pharmacophore model. The QSAR model was further treated as a template for in silico search of databases to identify new scaffolds. The binding patterns of the leads with A2A AR are analysed using docking studies and novel potent ligands of A2A AR are projected.

Acknowledgment

The authors K.K.M. and A.R.C. are grateful to, The Head, Department of Chemistry and The Principal, Nizam College for the facilities and acknowledge Dr. P. Sarita Rajender, Ms. D. Ramasree, Ms. K. Bhargavi and Ms. M. Vasavi for helpful discussions.

Declaration of interest

The authors declare no conflict of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.